U.S. markets open in 2 hours 21 minutes

Y-mAbs Therapeutics, Inc. (YMAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.85+0.62 (+1.87%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close33.23
Open33.19
Bid0.00 x 900
Ask0.00 x 1000
Day's Range33.19 - 34.08
52 Week Range24.78 - 55.22
Volume100,792
Avg. Volume235,715
Market Cap1.475B
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Y-mAbs Therapeutics, Inc.
    Analyst Report: United Therapeutics CorpUnited Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for patients with cardiovascular conditions, cancer and infectious diseases. It has five approved products on the market and a strong new product pipeline. The company has roughly 950 employees and is a component of the S&P 400.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

    NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) f

  • GlobeNewswire

    Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

    NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET. This webinar will feature presentati

  • Benzinga

    Y-Mabs Therapeutics Trades $1.76 Million In Company Stock

    Thomas Gad, Y-Mabs Therapeutics (NASDAQ:YMAB) insider, made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 7, Thomas Gad bought 50,000 Y-Mabs Therapeutics shares at a price of $2.00 per share, for a total of $100,000. They then sold their shares on the same day in the open market at a price of $33.18 to raise a total of $1,658,915 from the sale. Followi